Open AccessImmunotherapy beyond cellular therapy in follicular lymphoma: A case of complete remission after failure of two CAR‐T
Author(s) -
Kase Adam M.,
KharfanDabaja Mohamed A.,
Donaldson Andrew,
Elliott Jamie,
Sher Taimur
Publication year - 2022
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.5572
Subject(s) - medicine , lenalidomide , follicular lymphoma , obinutuzumab , lymphoma , refractory (planetary science) , complete remission , follicular phase , oncology , rituximab , chemotherapy , multiple myeloma , physics , astrobiology
Patients with relapsed follicular lymphoma who do not respond to CAR‐T have a poor outcome. We present a case of refractory follicular lymphoma who relapsed after two CAR‐T infusions and achieved a complete remission after treatment with obinutuzumab and lenalidomide. This represents a promising treatment option in the post‐CAR‐T setting.